- Oops!Something went wrong.Please try again later.
Shares of BioDelivery Sciences Intl (NASDAQ:BDSI) rose 6.1% in pre-market trading after the company reported Q4 results.
Earnings per share rose 66.67% year over year to $0.10, which beat the estimate of $0.06.
Revenue of $42,167,000 rose by 33.28% from the same period last year, which beat the estimate of $38,720,000.
The upcoming fiscal year's revenue expected to be between $170,000,000 and $180,000,000.
Conference Call Details
Date: Mar 10, 2021
Time: 08:30 AM
Company's 52-week high was at $5.45
52-week low: $2.85
Price action over last quarter: Up 29.46%
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.